

# 1 **Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial**

2 **Authors:** Sergio Fragoso-Saavedra, M.D., Isaac Núñez, M.D., Belem M. Audelo-Cruz, M.D., Sarahi  
3 Arias-Martínez, M.D., Daniel Manzur-Sandoval, M.D., Alejandro Quintero-Villegas, M.D., H. Benjamín  
4 García-González, M.D., Sergio L. Carbajal-Morelos, M.D., Sergio Ponce de León-Rosales, M.D., José  
5 Gotés-Palazuelos, M.D., M.Sc., José A. Maza-Larrea, M.D., Yanink Caro-Vega, Ph.D., Isabella  
6 Batina, M.D., León Islas-Weinstein, M.D., Ph.D., David A. Iruegas-Nunez, M.D., Juan J. Calva, M.D.,  
7 M.Sc., Pablo F. Belaunzarán-Zamudio, M.D., M.Sc., Juan Sierra-Madero, M.D., José C. Crispín, M.D.,  
8 Ph.D., Sergio I. Valdés-Ferrer, M.D., Ph.D.

9

## 10 **Affiliations:**

11 Programa de Estudios Combinados en Medicina (MD/PhD Program), Facultad de Medicina,  
12 Universidad Nacional Autónoma de México (S.F.-S.), Mexico City, Mexico; Internal Medicine  
13 Residency Training Program, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán  
14 (I.N., A.Q.-V., H.B. G.-G., S.L.C.-M.), Mexico City, Mexico. Departamento de Neurología y Psiquiatría  
15 (B.M.A.-C., S.A.-M., I.B., D.A.I.-N., S.I.V.-F.); Educación Médica (S.P.deL.-R.); Medicina (J.G.-P.);  
16 Inmunología y Reumatología (J.C.C.); and, Patología Experimental (L.I.-W.), Instituto Nacional de  
17 Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Escuela Superior de Medicina,  
18 Instituto Politécnico Nacional (B.M.A.-C.), Mexico City, Mexico. Instituto Nacional de Cardiología  
19 Ignacio Chávez (D.M.-S.; J.A.M.-L.), Mexico City, Mexico. Infectología (S.F.-S., Y.C.-V., J.J.C., J.S.-  
20 M., S.I.V.-F.); Escuela Nacional de Medicina y Ciencias de la Salud, Instituto Tecnológico y de  
21 Estudios Superiores de Monterrey (D.A.I.-N., J.C.C), Monterrey, Mexico. Division of AIDS, National  
22 Institute of Allergy and Infectious Diseases, National Institutes of Health (P.F.B.-Z.), Rockville, MD,  
23 USA. Center for Biomedical Science, Feinstein Institutes for Medical Research (S.I.V.-F.), Manhasset,  
24 NY, USA.

25

26 **Address correspondence to:** Sergio I. Valdés-Ferrer, Departamento de Neurología y Psiquiatría,  
27 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Phone:  
28 +52(55)5487-0900, ext. 4177. Email: [sergio.valdesf@incmnsz.mx](mailto:sergio.valdesf@incmnsz.mx)

29

30 **Abstract**

31 **Background:** Hospitalized patients with severe COVID-19 have an increased risk of developing  
32 severe systemic inflammatory response, pulmonary damage, and acute respiratory distress syndrome  
33 (ARDS), resulting in end-organ damage and death. Acetylcholine modulates the acute inflammatory  
34 response through a neuro-immune mechanism known as the inflammatory reflex. Pyridostigmine, an  
35 acetylcholine-esterase inhibitor, increases the half-life of endogenous ACh, chemically stimulating the  
36 inflammatory reflex. This trial aimed to evaluate whether pyridostigmine could decrease invasive  
37 mechanical ventilation (IMV) and death in patients with severe COVID-19.

38 **Methods:** We performed a parallel-group, multicenter, double-blinded, placebo-controlled,  
39 randomized clinical trial to evaluate if add-on pyridostigmine to standard treatment reduced the  
40 composite outcome of initiation of IMV and 28-day all-cause mortality among hospitalized patients with  
41 severe COVID-19.

42 **Results:** 188 participants were randomly assigned to placebo (n=94) or pyridostigmine (n=94). The  
43 composite outcome occurred in 22 (23.4%) vs. 11 (11.7%) participants, respectively (hazard ratio  
44 0.46, 95% confidence interval 0.22-0.96,  $p=0.03$ ). Most of the adverse events were mild to moderate,  
45 with no serious adverse events related to pyridostigmine; discontinuation of the study drugs was  
46 similar in both groups.

47 **Conclusions:** We provide evidence indicating that the addition of pyridostigmine to standard  
48 treatment resulted in a clinically significant reduction in the composite outcome (IMV/death) among  
49 patients hospitalized for severe COVID-19. (Funded by Consejo Nacional de Ciencia y Tecnología,  
50 México; ClinicalTrials.gov number: NCT04343963).

51

## 52 INTRODUCTION

53 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus  
54 disease 2019 (COVID-19)<sup>1</sup>, may lead to severe systemic inflammatory response<sup>2</sup>, acute respiratory  
55 distress syndrome<sup>3</sup>, multiple-organ failure, resulting and death<sup>4,5</sup>.

56 Among several drugs evaluated in clinical trials to mitigate COVID-19 severity, dexamethasone has  
57 been shown to reduced mortality among patients requiring supplementary oxygen. However, its use is  
58 accompanied by frequent adverse effects such as hyperglycemia, psychosis, and gastrointestinal  
59 hemorrhage<sup>6</sup>. Remdesivir, an antiviral, alone or in combination with baricitinib, a selective inhibitor of  
60 Janus kinases 1 and 2, accelerated recovery and reduced in-hospital stay, without a significant effect  
61 on mortality<sup>7,8</sup>. Hence, therapeutic interventions able to ameliorate the morbidity and mortality caused  
62 by SARS-CoV2 are urgently needed.

63 The central nervous system regulates the inflammatory response via the release of acetylcholine by  
64 the vagus nerve, reducing the production of inflammatory mediators, through the *inflammatory reflex*<sup>9</sup>.  
65 Choline-acetyltransferase (ChAT)-expressing T cells modulate inflammation via *in situ* release of  
66 acetylcholine<sup>10</sup> and this effect is critical in reducing viremia in animal models of viral infection<sup>11</sup>.  
67 Pyridostigmine, an acetylcholinesterase inhibitor (i-ACh-e), increases acetylcholine (ACh) half-life by  
68 inhibiting its peripheral degradation. Pyridostigmine is used for the symptomatic treatment of  
69 myasthenia gravis<sup>12</sup> and as pre-exposure prophylaxis for nerve gas poisoning<sup>13</sup>. Importantly,  
70 pyridostigmine decreases inflammation in chronic human immunodeficiency virus (HIV)-1 infection<sup>14-</sup>  
71 <sup>16</sup>. This study aimed to determine whether pyridostigmine administration could improve the outcome of  
72 patients with severe COVID-19.

## 73 METHODS

### 74 Aim, study design, and settings

75 Our main aim was to evaluate, in a controlled setting, the efficacy of pyridostigmine as an adjunct  
76 therapy to reduce the incidence of critical illness or death in hospitalized adults with severe COVID-19.

77 We performed a double-blinded, placebo-controlled, parallel randomized clinical trial. Participants  
78 were allocated (1:1 ratio) to receive, in addition to standard medical treatment, either oral  
79 pyridostigmine at a dose of 60 mg/day P.O. or a matching placebo (pharmaceutical-grade starch) until  
80 the occurrence of any of the prespecified outcomes, hospital discharge, or 14 in-hospital days. The  
81 primary outcome was a composite of invasive mechanical ventilation (IMV) or death in the 28 days  
82 following randomization (Fig. 1). Secondary outcomes were not prespecified and included: (a) the  
83 length of in-hospital days after randomization; (b) hospital discharge by day-28; (c) among those who  
84 required IMV, the number of days with, and the survival rate after IMV; (d) failure to complete  
85 treatment as expected due to adverse events (other than the primary composite outcome).

86 Adverse events (AEs) were collected using data obtained from the medical health records of each  
87 study participant. The events were evaluated and coded using the Medical Dictionary and Regulatory  
88 Activities (MedDRA) version 24.0 browser and the severity of the AEs was assessed by the National  
89 Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

90 Although not used throughout the study, unblinding was allowed in case of severe adverse events at  
91 the request of either the treating group of physicians or the external Data and Safety Monitoring Board  
92 (DSMB). The study was conducted in two parts, as already described<sup>17</sup>: a phase 2 aimed at  
93 determining safety (May 5 to July 4, 2020), followed by a phase 3 aimed at evaluating the effect -or  
94 lack thereof- of pyridostigmine in patients with severe COVID-19 (July 5, 2020, to January 30, 2021).  
95 Participants in both phases were included in the analyses of outcomes.

## 96 **Study population**

97 Adult ( $\geq 18$ -year-old) hospitalized patients with confirmed SARS-CoV-2 infection based on a positive  
98 RT-PCR test for SARS-CoV-2 RNA in a respiratory specimen (nasopharyngeal or nasal swab), an  
99 imaging study compatible with pneumonia, and at least one risk factor for requiring IMV or dying  
100 (Figure 1). The full list of inclusion, exclusion and elimination criteria has been published<sup>17</sup>.

101 Participants were randomized in a 1:1 ratio, with a parallel assignment and block-randomization  
102 approach using a publicly available online resource ([www.randomizer.org](http://www.randomizer.org)).

103 We collected demographic information from participants at baseline, including age, sex, and  
104 comorbidities (including diabetes mellitus, hypertension, obesity, cardiovascular disease, lung  
105 disease, or other chronic medical conditions). Participants already discharged from the hospital by day  
106 28, including those who were transferred to another facility, were contacted by telephone to assess  
107 their vital and functional status.

108 This bicentric study was carried out at Instituto Nacional de Ciencias Médicas y Nutrición Salvador  
109 Zubirán, and Instituto Nacional de Cardiología Ignacio Chávez, two COVID-19-designated Hospitals in  
110 Mexico City, Mexico.

111

## 112 **Study design and sample-size calculation**

113 The trial was planned and approved in March 2020; funding was obtained in April 2020, shortly after  
114 the first case of COVID-19 was diagnosed in Mexico. At that time, we relied on limited information  
115 about clinical outcomes in these patients. Thus, we calculated a sample size of 436 participants  
116 considering an event rate of 25% in the control group, considering a 10% absolute reduction (40%  
117 relative reduction) in the primary outcome as clinically significant, and 80% power to detect a  
118 difference in the primary outcome using a two-sided significance level of  $\alpha=0.05$ <sup>17</sup>. However, the  
119 sample size would be adjusted according to interim analyses. The first participant was recruited on  
120 May 5<sup>th</sup>, 2020. The DSMB performed an interim analysis after the first 44 participants (22 per group,  
121 10% of the calculated sample) to evaluate safety on July 4<sup>th</sup>, 2020; a second interim analysis was  
122 conducted on December 7<sup>th</sup>, 2020 including 28-day outcomes on 100 participants (50 per group). Due  
123 to an observed difference in the primary outcome between groups (still blinded to investigators, but  
124 unblinded to the DSMB), as well as difficulty recruiting new participants due to a reduction in eligible  
125 patients and a swell in competing studies, we decided to stop the trial after 188 participants had been  
126 recruited (94 in each group). Considering the same  $\alpha=0.05$ , we recalculated the statistical power of the  
127 obtained sample with the observed difference between groups (an absolute reduction of 11.7% and  
128 relative reduction of 50%), which resulted in ~85%.

## 129 **Statistical analyses**

130 We conducted an intention-to-treat analysis for the primary outcome that included all the patients who  
131 underwent randomization. As unplanned secondary outcomes, we assessed between-group  
132 differences of mechanical ventilation and death with or without IMV. Patients that had not developed  
133 an outcome by day 28 were censored at day 29. The magnitude of the effect of pyridostigmine on the  
134 primary outcome was estimated with a hazard ratio (HR) and its 95% confidence interval (CI)  
135 calculated with Cox proportional hazard model, as were IMV, and death with or without IMV, and  
136 discharge home although these secondary outcomes were not pre-specified in the study protocol. We  
137 built Kaplan Meier survival curves to plot the cumulative incidence of the primary outcome up to day-  
138 28. Statistical analysis was conducted with Prism GraphPad software, version 9.1.0 (GraphPad  
139 Software, San Diego, CA), and R version 4.0.0.

140

## 141 **RESULTS**

### 142 **Patients**

143 We assessed for eligibility 334 patients, of whom 201 accepted to participate; of those, thirteen  
144 patients were excluded for the following reasons: five withdrew consent after signing but before  
145 randomization; four were transferred to a different facility before randomization; three required IMV  
146 before randomization, and one was diagnosed with lung cancer (one of our exclusion criteria) during  
147 the initial assessment, therefore withdrawn from the study before randomization. In total, 188  
148 participants underwent randomization, 94 in each group, all of whom received at least one dose of the  
149 assigned intervention. Enrollment and randomization are shown in **Fig. 1**. Baseline demographic and  
150 clinical characteristics were balanced between groups (**Table 1**).

151 The median age of the patients was 52 years (interquartile range [IQR], 44 to 64 years), and 59.6 %  
152 were male. The most common preexisting conditions at enrollment were diabetes and hypertension  
153 (**Table 1**). The imbalance of obesity proportion between groups appeared clinically relevant (53.2% vs.

154 33%), so we performed a  $\chi^2$  test which also showed a statistically significant difference ( $p=0.005$ ).  
155 There were no relevant differences in the rest of the baseline characteristics between groups,  
156 including the number of patients who received dexamethasone or tocilizumab as part of in-hospital  
157 medical management (**Table 1**). All participants were hypoxemic and received supplementary oxygen  
158 as part of in-patient management. The median interval from symptom onset to randomization was 10  
159 days (IQR, 9 to 12 days). The median interval from hospital admission to randomization was 2 days  
160 (IQR, 1 to 3 days). Dexamethasone was administered to 140 participants (69 on the pyridostigmine  
161 group and 71 on the placebo group). Tocilizumab was administered to 10 participants (5 on the  
162 pyridostigmine group, and 5 on the placebo group). None of the participants received remdesivir

### 163 **Primary outcome**

164 Thirty-three participants met the primary outcome by day 28; 11 (11.7%) in the pyridostigmine group  
165 and 22 (23.4%) in the control group (HR 0.47, 95% CI 0.23-0.95,  $p=0.03$ ) (**Fig. 2**). As obesity status  
166 differed between study groups, we performed an unplanned sensitivity analysis with a Cox  
167 proportional hazards model adjusted for obesity status. We excluded 10 patients (four from the  
168 pyridostigmine group and six from the control group) that had no information on obesity status (of  
169 which only one had a primary outcome) for this sensitivity analysis, obtaining an adjusted HR of 0.42  
170 (95% CI 0.19-0.91) for the primary outcome, 0.78 (95%CI 0.24-2.54) for IMV, and 0.32 (95%CI 0.13-  
171 0.77) for death.

### 172 **Secondary outcomes**

173 IMV was initiated in 6 (6.4%) patients in the pyridostigmine group and 7 (7.5%) in the placebo group  
174 (HR 0.81, 95%CI 0.27-2.42). The median duration of IMV was 15 days (IQR, 10 to 23) in the  
175 pyridostigmine group and 17 days (IQR, 7 to 39) in the placebo group. The survival rate after IMV was  
176 66.7% (four patients) in the pyridostigmine group and 42.9% (three patients) in the placebo group.  
177 A total of 26 patients died by day 28, 7 in the pyridostigmine group and 19 in the placebo group (HR  
178 0.33, 95%CI 0.14-0.81). All of the deaths in the pyridostigmine group occurred in the study center



179 while three in the placebo group happened after the patient was transferred to another center. The  
180 median duration of in-hospital stay after randomization (censored at day 29) was 5 days (IQR, 3 to 10  
181 days) in the pyridostigmine group and 5 days (IQR, 3 to 8 days) in the placebo group. The twenty-  
182 eight-day hospital discharge rate was 90.4% (85 patients) in the pyridostigmine group and 75.5% (71  
183 patients) in the control group (Table 2 and Fig. 3). The use of dexamethasone was well balanced  
184 between groups (69 in the pyridostigmine group and 71 in the placebo group). A higher proportion of  
185 outcomes occurred among patients in the placebo group that did not use dexamethasone (35% of  
186 them had an outcome vs 20% of those who did use dexamethasone). The numbers in the  
187 pyridostigmine group were 8% and 13% (did not use and did use, respectively).

188 We collected and analyzed 83 AEs throughout the study. Overall, 45 (47.9%) patients of the  
189 pyridostigmine group and 38 (40.4%) of the placebo group had at least one adverse drug reaction.  
190 The rate and severity of AEs were similar between both groups (Supplemental Tables 1-3).

191 Of the 188 participants, 166 (88.3%) received experimental treatment as assigned during their in-  
192 hospital stay; 22 (11.7%) discontinued treatment early, nine (9.5%) in the pyridostigmine group, and  
193 13 (13.8%) in the placebo group. Two participants in each group discontinued trial medication due to  
194 an adverse event other than the principal outcome: one patient presented nausea and one mild  
195 abdominal pain in the pyridostigmine group (known adverse effects of pyridostigmine), and in the  
196 placebo group one patient had pyrosis and one presented diarrhea. The remaining patients  
197 discontinued trial medication after being transferred to another facility (Fig. 1)

## 198 **DISCUSSION**

199 Here, we show that added to standard care, pyridostigmine is associated with decreased IMV and  
200 mortality in patients hospitalized for severe COVID-19. This was driven by a decrease in all-cause  
201 mortality in the pyridostigmine group compared to that of the placebo group (by 12.7 percentage  
202 points). IMV was an infrequent outcome, which explains the lack of difference when analyzing this  
203 outcome by itself. Also, the adjunct use of pyridostigmine increased the probability of being discharged  
204 from the hospital alive within 28 days.

205 Early reports estimated mortality rates as high as 49% for hospitalized patients with severe COVID-  
206 19<sup>18</sup>. Although the in-hospital mortality rate has been declining throughout the pandemic, recent  
207 studies still show rates ranging from 20 to over 40%<sup>19-21</sup>. The risk of death still exceeded 20% in the  
208 dexamethasone and tocilizumab arms of the RECOVERY trial, being the only two treatments so far  
209 that have shown a decrease in mortality<sup>6, 21</sup>.

210 The severity and mortality of COVID-19 are mediated by the development of a pathologically intense  
211 inflammatory response to infection since elevated levels of proinflammatory cytokines and other  
212 immune mediators have been associated with multiorgan failure due to endothelial damage and tissue  
213 injury<sup>3,5</sup>. Hence, finding novel immunomodulatory strategies represents a promising strategy to reduce  
214 the severity and mortality of COVID-19. This, along with the repurposing of drugs with well-  
215 characterized safety profiles and readily available production lines, might lead to faster development of  
216 anti-COVID-19 therapies if proven efficacious in well-designed, randomized clinical trials.

217 In mammals, the central nervous system has mechanisms to control the inflammatory response.  
218 During inflammatory states, the vagus nerve can inhibit the synthesis and release of inflammatory  
219 cytokines<sup>22</sup>, thereby reducing both local damage and mortality secondary to severe systemic  
220 inflammation in murine models as diverse as sepsis, ischemia, and reperfusion damage, or obesity<sup>22-  
221 25</sup>. The vagus nerve can be stimulated electrically and chemically. Chemical stimulation using  
222 cholinergic agonists has shown promising effects in murine and cellular models of inflammation<sup>25,26</sup>.  
223 Acetylcholine esterase inhibitors (i-ACh-e) are a family of drugs used regularly by millions of patients,  
224 including older adults with Alzheimer's disease and other dementias, as well as patients with  
225 myasthenia gravis and dysautonomia<sup>12,27-30</sup>. These drugs inhibit the enzymatic degradation of  
226 endogenous ACh, resulting in greater bioavailability and, therefore, increasing the possibility of binding  
227 to both nicotinic and muscarinic receptors. In addition to the approved uses of i-ACh-e in human  
228 pathology, there is evidence in various murine models of their efficacy in experimental sepsis and  
229 severe inflammatory response<sup>23,24,26</sup>, suggesting that i-ACh-e drugs may exert a potential  
230 immunomodulatory effect in patients with severe systemic inflammatory response syndrome.

231 Pyridostigmine, an acetylcholinesterase inhibitor, has been previously shown to decrease  
232 inflammation in people living with human immunodeficiency virus (HIV) infection<sup>14–16</sup>. Regarding safety  
233 concerns, at the used dose of pyridostigmine, the rate of adverse events we observed was 47.9%,  
234 none of them severe and it was no different from the observed in the placebo group (40.4%). The  
235 reduction in mortality in patients with severe COVID-19 who received pyridostigmine may be due to an  
236 immunomodulatory effect, however, its precise biological effect in this novel disease remains to be  
237 studied. Different immunomodulatory strategies have been tested that have sought to selectively  
238 inhibit the biological activity of certain pro-inflammatory cytokines, such as IL-6<sup>31</sup>; however, the global  
239 inhibition of several of them by pharmacologically stimulating the inflammatory reflex could be more  
240 effective, which is the effect sought with the administration of pyridostigmine.

241 Our study has important limitations. The originally planned sample size could not be achieved. Still, a  
242 significant difference was observed because of a greater than expected effect. Also, it is possible that  
243 some patients requiring IMV could not receive it because of either, a pre-existing living will; last-minute  
244 patient (or proxy) refusal of intubation; or, intermittently throughout the study period, hospital  
245 saturation of critical-care beds<sup>19,20</sup>. Our outcome included starting, but not necessarily the requirement  
246 of, IMV. This is reflected in the fact that the bulk of the primary outcome was due to deaths without  
247 receiving IMV, most likely due to lack of critical care space. Thus, our results may not be generalizable  
248 to places that do not have this problem. Importantly, we do not have a disease severity measure at  
249 randomization, so groups could be imbalanced in this sense. Nonetheless, both groups should be  
250 equally affected by this limitation. As a proof-of-concept, this study needs to be replicated or refuted in  
251 independent clinical trials. Also, at this point, our results cannot be extrapolated to patients with less  
252 severe disease, or those already receiving IMV, without prior verification in clinical trials. Finally,  
253 medium-term outcomes (90 days) will be reported at a later time point.

254 The strengths of the study include that it is a double-blinded placebo-controlled multicentric  
255 randomized clinical trial that evaluated an inexpensive treatment, has a positive pharmacological  
256 profile, is safe, and is widely available in a generic presentation. The demographics of our study

257 population, including age and comorbid conditions, are representative of a large group of the  
258 underserved population worldwide (particularly across the Americas), a population in urgent need of  
259 safe, effective, life-saving, and affordable treatments for severe COVID-19.

260 In conclusion, we present compelling evidence to support the use of pyridostigmine as an add-on  
261 treatment to standard medical care in patients hospitalized for severe COVID-19. Our data indicate  
262 that this inexpensive drug may significantly reduce mortality without imposing relevant adverse effects.

263 **Acknowledgments:** This study was funded by Consejo Nacional de Ciencia y Tecnología, Mexico  
264 (COVID-19 Fund [F0005-2020-01]; grant 311790), to SIV-F]. The authors are grateful to Claudia  
265 Quiñones, B.Ch. and, Elia Criollo-Mora, B.Ch. for preparing, packing, masking, and labeling active and  
266 placebo pills, as well as overseeing drug dispensing. The authors are grateful to Dr. Virginia Pascual-  
267 Ramos for providing ethical and statistical recommendations throughout the study.

268

269 **Table 1. Clinical and demographical characteristics of patients at baseline.**

Variables	All (N=188)	Pyridostigmine (N=94)	Placebo (N=94)
Sex - no. (%)	-	-	-
Male	112 (59.6)	56 (59.6)	56 (59.6)
Female	76 (40.4)	38 (40.4)	38 (40.4)
Age	-	-	-
Median (IQR) - yr	52 (44-64)	51 (43-63)	54 (46-66)
Previous coexisting disease - no. (%)	-	-	-
Diabetes	68 (36.2)	33 (35.1)	35 (37.2)
Hypertension	66 (35.1)	33 (35.1)	33 (35.1)
Heart disease	4 (2.1)	2 (2.1)	2 (2.1)
Chronic lung disease	8 (4.3)	6 (6.4)	2 (2.1)
Obesity**	81 (43.1)	50 (53.2)	31 (33)
Median BMI (IQR) – kg/m <sup>2</sup>	29 (26.5-33)	30.25 (26.5-33.4)	28.1 (26.5-31.45)
Median time (IQR) from symptom onset to randomization - days	10 (9-12)	10 (8-11)	10 (9-13)
Median time (IQR) from admission to randomization – days	2 (1-3)	2 (1-2)	2 (1-3)
Other immunomodulators used by medical team – no. (%)	-	-	-
Dexamethasone	140 (74.5)	69 (73.4)	71 (75.5)
Tocilizumab	10 (5.3)	5 (5.3)	5 (5.3)

270 **\*\*BMI information is not available for 10 patients, four in the pyridostigmine group and six in**  
 271 **the placebo group.**

272

273

274 **Table 2. Primary and secondary outcomes by day 28.**

Outcomes	All (N=188)	Pyridostigmine (N=94)	Placebo (N=94)	HR (95% CI)
Primary outcome				
Invasive mechanical ventilation or death – no. (%)	33 (17.5%)	11 (11.7%)	22 (23.4%)	0.47 (0.23-0.95)
Secondary outcomes				
Invasive mechanical ventilation – no. (%)	13 (6.9%)	6 (6.3%)	7 (7.4%)	0.81 (0.27-2.42)
Median time (IQR) in ICU with invasive mechanical ventilation - days	17 (11-23)	15 (15-21)	17 (12-30)	-
Survival after IMV – no. (%)	7 (53.8)	4 (66%)	3 (42.9)	-
Death - no. (%)	26 (13.8%)	7 (7.4%)	19 (20.2%)	0.33 (0.14-0.81)
*Median time (IQR) from randomization to discharge home – days	5 (3-9)	5 (3-10)	5 (3-8)	-
Discharge home by day 28 – no. (%)	156 (82.9)	85 (90.4)	71 (75.5)	1.13 (0.82-1.55)
Adverse events - no. (%)	83 (44.1)	45 (47.9)	38 (40.4)	-
Failure to complete treatment due to adverse effects – no. (%)	4 (2)	2 (2)	2 (2)	-

275 \*For time to discharge home in patients that were transferred, the time from randomization until  
 276 discharge home from the hospital that they were transferred to was used. Two patients did not have  
 277 this information available but were discharged home alive. For them, the date of transfer was used.  
 278 Patients that were still in the hospital on day 28 were censored on day 29.

279

280 **FIGURE LEGENDS**

281 **Figure 1. Enrollment and randomization.**

282 **Figure 2. Time to Mechanical Ventilation or Death by Day 28.**

283 **Figure 3. Time to Mechanical Ventilation, Death or Discharge Home by Day 28 as Separate**

284 **Outcomes.** A) IMV as the primary outcome; B) death as the primary outcome; and, C) Discharge

285 home as the primary outcome. Hazard ratios were calculated with Cox proportional hazards models.

286 In the case of IMV as the primary outcome, deaths without IMV were censored. In the case of death

287 as the primary outcome, IMV was not taken into account. In the case of discharge home as the

288 primary outcome, IMV, deaths, and hospital transfers were censored.

289

290 **References**

- 291 1 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in China,  
292 2019. *N Engl J Med* 2020; **382**: 727–33.
- 293 2 Xu Z, Shi L, Wang Y, *et al.* Pathological findings of COVID-19 associated with acute respiratory  
294 distress syndrome. *Lancet Respir Med* 2020; **8**: 420–2.
- 295 3 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus  
296 in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- 297 4 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19  
298 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; **46**:  
299 846–8.
- 300 5 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider  
301 cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033–4.
- 302 6 Horby P, Lim WS, Emberson J, *et al.* Dexamethasone in Hospitalized Patients with Covid-19. *N*  
303 *Engl J Med* 2021; **384**: 693–704.
- 304 7 Beigel JH, Tomashek KM, Dodd LE, *et al.* Remdesivir for the Treatment of Covid-19 — Final  
305 Report. *N Engl J Med* 2020; **383**: 1813–26.
- 306 8 Kalil AC, Patterson TF, Mehta AK, *et al.* Baricitinib plus Remdesivir for Hospitalized Adults with  
307 Covid-19. *N Engl J Med* 2021; **384**: 795–807.
- 308 9 Borovikova L V., Ivanova S, Zhang M, *et al.* Vagus nerve stimulation attenuates the systemic  
309 inflammatory response to endotoxin. *Nature* 2000; **405**: 458–62.
- 310 10 Rosas-Ballina M, Olofsson PS, Ochani M, *et al.* Acetylcholine-synthesizing T cells relay neural  
311 signals in a vagus nerve circuit. *Science (80- )* 2011; **334**. DOI:10.1126/science.1209985.
- 312 11 Cox MA, Duncan GS, Lin GHY, *et al.* Choline acetyltransferase–expressing T cells are required




- 313 to control chronic viral infection. *Science (80- )* 2019; **363**: 639–44.
- 314 12 Gilhus NE, Verschuuren JJ. Myasthenia gravis: Subgroup classification and therapeutic  
315 strategies. *Lancet Neurol* 2015; **14**: 1023–36.
- 316 13 Keeler JR, Hurst CG, Dunn MA. Pyridostigmine Used as a Nerve Agent Pretreatment Under  
317 Wartime Conditions. *JAMA J Am Med Assoc* 1991; **266**: 693–5.
- 318 14 Valdés-Ferrer SI, Crispín JC, Belaunzarán PF, Cantú-Brito CG, Sierra-Madero J, Alcocer-  
319 Varela J. Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in  
320 patients infected by HIV. *AIDS Res Hum Retroviruses* 2009; **25**. DOI:10.1089/aid.2008.0257.
- 321 15 Valdés-Ferrer SI, Crispín JC, Belaunzarán-Zamudio PF, *et al.* Add-on Pyridostigmine enhances  
322 CD4+ T-cell recovery in HIV-1-infected immunological non-responders: A proof-of-concept  
323 study. *Front Immunol* 2017; **8**: 1–6.
- 324 16 Robinson-Papp J, Nmashie A, Pedowitz E, *et al.* The effect of pyridostigmine on small intestinal  
325 bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic  
326 neuropathies. *J Neurovirol* 2019; **25**: 551–9.
- 327 17 Fragoso-Saavedra S, Iruegas-Nunez DA, Quintero-Villegas A, *et al.* A parallel-group,  
328 multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the  
329 efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical  
330 ventilation in adults with severe SARS-CoV-2 inf. *BMC Infect Dis* 2020; **20**: 765.
- 331 18 Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease  
332 2019(COVID-19) outbreak in China. *Jama* 2020; **2019**: 10.1001/jama.2020.2648.
- 333 19 Rossman H, Meir T, Somer J, *et al.* Hospital load and increased COVID-19 related mortality in  
334 Israel. *Nat Commun* 2021; **12**: 1–7.
- 335 20 Olivas-Martínez A, Cárdenas-Fragoso JL, Jiménez JV, *et al.* In-hospital mortality from severe  
336 COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact


- 337 of hospital saturation. *PLoS One* 2021; **16**: e0245772.
- 338 21 de Souza FSH, Hojo-Souza NS, Batista BD de O, da Silva CM, Guidoni DL. On the analysis of  
339 mortality risk factors for hospitalized COVID-19 patients: A data-driven study using the major  
340 Brazilian database. *PLoS One* 2021; **16**: e0248580.
- 341 22 Yeboah MM, Xue X, Duan B, *et al.* Cholinergic agonists attenuate renal ischemia-reperfusion  
342 injury in rats. *Kidney Int* 2008; **74**: 62–9.
- 343 23 Satapathy SK, Ochani M, Dancho M, *et al.* Galantamine alleviates inflammation and other  
344 obesity-associated complications in high-fat diet-fed mice. *Mol Med* 2011; **17**.  
345 DOI:10.2119/molmed.2011.00083.
- 346 24 Zaghloul N, Addorisio ME, Silverman HA, *et al.* Forebrain cholinergic dysfunction and systemic  
347 and brain inflammation in murine sepsis survivors. *Front Immunol* 2017; **8**.  
348 DOI:10.3389/fimmu.2017.01673.
- 349 25 Lehner KR, Silverman HA, Addorisio ME, *et al.* Forebrain cholinergic signaling regulates innate  
350 immune responses and inflammation. *Front Immunol* 2019; **10**: 1–11.
- 351 26 Rosas-Ballina M, Valdés-Ferrer SI, Dancho ME, *et al.* Xanomeline suppresses excessive pro-  
352 inflammatory cytokine responses through neural signal-mediated pathways and improves  
353 survival in lethal inflammation. *Brain Behav Immun* 2015; **44**: 19–27.
- 354 27 Mayeux R. Clinical practice. Early Alzheimer's disease. *N Engl J Med* 2010; **362**: 2194–201.
- 355 28 Querfurth HW, Laferla FM. Alzheimer's Disease. *N Engl J Med* 2018; **326**: 329–44.
- 356 29 O'Brien JT, Thomas A. Vascular dementia. *Lancet* 2015; **386**: 1698–706.
- 357 30 Singer W, Sandroni P, Opfer-Gehrking TL, *et al.* Pyridostigmine treatment trial in neurogenic  
358 orthostatic hypotension. *Arch Neurol* 2006; **63**: 513–8.
- 359 31 Salama C, Han J, Yau L, *et al.* Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.

360 *N Engl J Med* 2021; **384**: 20–30.

361


**Figure 1. Enrollment and randomization**






**No. at risk**

Placebo	94	80	75	72	72
Pyridostigmine	94	88	85	84	83




**No. at risk**

Placebo	94	80	75	72	72
Pyridostigmine	94	88	85	84	83



**No. at risk**

Placebo	94	84	81	77	75
Pyridostigmine	94	93	89	88	87



**No. at risk**

Placebo	94	31	13	6	4
Pyridostigmine	94	36	13	9	2